Breast-Cancer Adjuvant Therapy with Zoledronic Acid | Zendy

Robert E. Coleman | Zendy; Helen Marshall | Zendy; David Cameron | Zendy; David Dodwell | Zendy; Roger Burkinshaw | Zendy; Maccon Keane | Zendy; Miguel GilGil | Zendy; Stephen Houston | Zendy; Robert Grieve | Zendy; Peter BarrettLee | Zendy; Diana Ritchie | Zendy; Julia Pugh | Zendy; Claire Gaunt | Zendy; Una Rea | Zendy; Jennifer Peterson | Zendy; Claire Davies | Zendy; Victoria Hiley | Zendy; Walter M. Gregory | Zendy; Richard H. Bell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

Author(s) -

Robert E. Coleman,

Helen Marshall,

David Cameron,

David Dodwell,

Roger Burkinshaw,

Maccon Keane,

Miguel GilGil,

Stephen Houston,

Robert Grieve,

Peter BarrettLee,

Diana Ritchie,

Julia Pugh,

Claire Gaunt,

Una Rea,

Jennifer Peterson,

Claire Davies,

Victoria Hiley,

Walter M. Gregory,

Richard H. Bell

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1105195

Subject(s) - zoledronic acid , medicine , hazard ratio , adjuvant therapy , breast cancer , adjuvant , clinical endpoint , confidence interval , surgery , oncology , cancer , randomized controlled trial

Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research